BOSTON, May 9, 2014 /PRNewswire/ -- PAREXEL International
(NASDAQ: PRXL), a leading global biopharmaceutical services
organization, today announced that its Chairman and CEO,
Josef von Rickenbach, was named 2014
Immigrant Entrepreneur of the Year in Life Sciences by the
Immigrant Learning Center of Malden, Mass. He received the award
May 8, 2014, during the third annual
Immigrant Entrepreneur Awards Dinner in Cambridge, Mass.
A native of Switzerland, Mr.
von Rickenbach earned a B.A. in
Business Economics from the School of Business at the Lucerne
University of Applied Sciences. After graduating from
Harvard Business School in 1981, he
co-founded PAREXEL in Cambridge in
1982 as a biopharmaceutical regulatory consulting company.
Over 30 years, he transformed the company into one of the world's
top biopharmaceutical service providers, leading PAREXEL through
its IPO, multiple public offerings, and over 35 mergers and
acquisitions. In particular, he pioneered a multidisciplinary
and systems-oriented approach to outsourced clinical research,
bringing efficiencies, scalability and standardization to global
drug development.
Headquartered in Waltham,
Mass., PAREXEL today has more than 15,000 employees and
conducts clinical trials in over 100 countries. The company
recorded total service revenue of $1.7
billion in 2013, and ranked fifth in the Boston
Globe's "Globe 100" list of best performing public companies in
the state.
Mr. von Rickenbach's extensive
industry expertise puts him at the forefront of drug development
and management leadership. In 2013, he received the Henri
Termeer Innovative Leadership Award from the Massachusetts
Biotechnology Council (MassBio). He is a noted contributor to the
New England business community, serving on the Board of Directors
of NEHI (Network for Excellence in Health Innovation) and on the
Health Policy and Management Executive Council of the Harvard
School of Public Health. Additionally, he is a Vice Chair of
CEOs Against Cancer, sponsored by the American Cancer Society New
England Chapter, and holds board positions on several nonprofit
organizations.
"I am grateful for the opportunity to have launched a business
in Massachusetts. The state has provided us access to
outstanding scientific expertise, renowned educational institutions
and emerging biopharmaceutical and high technology industries that
helped fuel our growth," said Mr. von
Rickenbach. "I am particularly honored by this
recognition, which also reflects the collective contributions of
our thousands of employees around the world."
The annual Immigrant Entrepreneur Awards program is sponsored by
the Immigrant Learning Center (ILC) of Malden, Mass., a nonprofit organization that
helps immigrants and refugees become successful workers, parents
and community members through direct service programs and public
education. Their direct service program provides free
year-round English classes to immigrant and refugee
adults in Greater Boston. For more information, visit
http://www.ilctr.org.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
knowledge-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. Perceptive Informatics, Inc., a
subsidiary of PAREXEL, provides advanced technology solutions,
including medical imaging, to facilitate the clinical development
process. Headquartered near Boston,
Massachusetts, PAREXEL operates in 75 locations in 50
countries around the world, and has 15,335 employees. For
more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL and "Your Journey. Our Mission." are trademarks or
registered trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more
fully in the section entitled "Risk Factors" of the Company's
Quarterly Report on Form 10-Q for the fiscal quarter ended
December 31, 2013 as filed with the
SEC on January 31, 2014, which "Risk
Factors" discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
SOURCE PAREXEL International